| scholarly article | Q13442814 |
| P50 | author | Yehuda Patt | Q8051301 |
| Pranshu Bansal | Q87990946 | ||
| Fa Chyi Lee | Q124061141 | ||
| P2093 | author name string | Sang-Joon Lee | |
| Ruofei Du | |||
| Waheed Murad | |||
| Yanis Boumber | |||
| Ari D Baron | |||
| Ed Bedrick | |||
| Kim Steinberg | |||
| Mohammed H Fekrazad | |||
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| Two-sided confidence intervals for the single proportion: comparison of seven methods | Q28271313 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. | Q30317428 | ||
| Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study | Q33374394 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Epidemiology and molecular pathology of gallbladder cancer | Q34473041 | ||
| Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 | Q36035889 | ||
| Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. | Q36831414 | ||
| Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. | Q37588461 | ||
| A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers | Q37639577 | ||
| TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer | Q40686537 | ||
| First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study | Q42164090 | ||
| Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe, Statistics in Medicine 1998; 17:857-872. | Q51962858 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma | Q80522943 | ||
| Diversification and trends in biliary tree cancer among the three major ethnic groups in the state of New Mexico | Q83211536 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erlotinib | Q418369 |
| oxaliplatin | Q422327 | ||
| multicenter clinical trial | Q6934595 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 2042-2051 | |
| P577 | publication date | 2017-08-11 | |
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial | |
| P478 | volume | 6 |
Search more.